“ Emma Beavins reports that gridlock in the Biden administration on allowing schedule II substances, like Adderall for ADHD, to be prescribed via telehealth could roll back progress on virtual prescribing. Stakeholders fear time is running out to extend pandemic-era telehealth flexibilities before they expire.”
Wednesday, September 11, 2024
AMA study: The 4 largest PBMs control 70% of the market nationally
By Paige Minemyer
The four largest pharmacy benefit managers in the United States control 70% of the national market, according to new data from the American Medical Association.
Tuesday, September 10, 2024
Today, the FDA posted a warning letter issued to Root Bioscience Brands LLC, doing business as Naternal, for illegally selling cannabidiol (CBD), cannabigerol (CBG), and cannabinol (CBN) products for people and pets. Naternal makes unproven claims their products can treat multiple diseases in people including Alzheimer’s disease, substance use disorder, autism and high blood pressure. Naternal also makes unproven claims their hemp extract oil products for pets can treat conditions such as separation anxiety, pain, arthritis and skin ailments. The Naternal products that are the subject of the warning letter are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a) and 331(d). The FDA requested a response from the company within 15 working days stating how they will correct the violations.
Friday, September 6, 2024
On Wednesday, the FDA issued a Dear Veterinarian letter describing Federal requirements related to a veterinarian’s role in dispensing prescription animal drugs and to the establishment of a veterinarian-client-patient relationship in the course of practice, including telemedicine.
Wednesday, September 4, 2024
| SoloVital | Center for Drug Evaluation and Research (CDER) | Unapproved New Drugs/Misbranded | ||||
| MexHealth LLC d/b/a Al Natural E-Shop | Center for Drug Evaluation and Research (CDER) | Unapproved New Drugs/Misbranded |
Veterinarian-Client-Patient Relationships, Prescribing/Dispensing Animal Drugs and Telemedicine Federal Requirements Relevant to Aspects of Veterinary Practice
Veterinarian-Client-Patient Relationships, Prescribing/Dispensing Animal Drugs and Telemedicine
Federal Requirements Relevant to Aspects of Veterinary Practice
The FDA has received questions from interested parties about Federal requirements related to a veterinarian’s role in dispensing prescription animal drugs and to the establishment of a veterinarian-client-patient relationship (VCPR) in the course of practice. The following Q&As only cover the veterinarian’s obligations under Federal law. Veterinarians should also consult their state licensing boards to determine if there are additional requirements at the state or local level.
 |
Tuesday, September 3, 2024
Subscribe to:
Posts (Atom)